Puma Biotechnology
Puma Biotechnology, Inc.
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology Stock News (PBYI) - Page 2 - Public.com
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma shares nearly triple on drug news, but options smell 'fishy'
Puma Biotechnology Inc Share Price USD0.0001
Stocks to Watch: Dropbox, Nike, Tronc, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
Puma shares nearly triple on drug news, but options smell 'fishy'
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - STAT
Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib | Seeking Alpha
Conspiracy Theory: Did Puma Biotech Exec Resign Because of Bad News Ahead? | BioSpace
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
